{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T22:31:11Z","timestamp":1781476271626,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":173,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG025152"],"award-info":[{"award-number":["AG025152"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG064589"],"award-info":[{"award-number":["AG064589"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K24 AG075234-01"],"award-info":[{"award-number":["K24 AG075234-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA048001"],"award-info":[{"award-number":["DA048001"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS099129"],"award-info":[{"award-number":["NS099129"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13311-023-01344-w","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:02:48Z","timestamp":1677762168000},"page":"375-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Channeling of New Neuropsychiatric Drugs\u2014Impact on Safety and Effectiveness Studies"],"prefix":"10.1016","volume":"20","author":[{"given":"Danielle S.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Phuong Pham","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah J.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-7192","authenticated-orcid":false,"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-023-01344-w_bib1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1210","article-title":"Using real-world data to extrapolate evidence from randomized controlled trials","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-023-01344-w_bib2","unstructured":"U.S. Food & Drug Administration. 2015\u20132019 Drug trials snapshots summary report: five-year summary and analysis of clinical trial participation and demographics [online]. 2020. Accessed at: https:\/\/www.fda.gov\/media\/143592\/download. Accessed 13 Nov 2020."},{"issue":"Suppl 1","key":"10.1007\/s13311-023-01344-w_bib3","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","article-title":"Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change","volume":"100","author":"Herrera","year":"2010","journal-title":"Am J Public Health"},{"key":"10.1007\/s13311-023-01344-w_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-023-01344-w_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cpt.857","article-title":"When and how can real world data analyses substitute for randomized controlled trials?","volume":"102","author":"Franklin","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-023-01344-w_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Social Adm Pharm"},{"key":"10.1007\/s13311-023-01344-w_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects","volume":"10","author":"Petri","year":"1991","journal-title":"Stat Med"},{"key":"10.1007\/s13311-023-01344-w_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/clpt.2011.235","article-title":"Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development","volume":"90","author":"Schneeweiss","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-023-01344-w_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1007\/s13311-023-01344-w_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jval.2013.05.008","article-title":"Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research","volume":"16","author":"Gagne","year":"2013","journal-title":"Value Health"},{"key":"10.1007\/s13311-023-01344-w_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CLEP.S124054","article-title":"Assessment of channeling bias among initiators of glucose-lowering drugs: a UK cohort study","volume":"9","author":"Ankarfeldt","year":"2017","journal-title":"Clin Epidemiol"},{"key":"10.1007\/s13311-023-01344-w_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/EDE.0000000000000020","article-title":"Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies","volume":"25","author":"Franklin","year":"2014","journal-title":"Epidemiology"},{"key":"10.1007\/s13311-023-01344-w_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1007\/s13311-023-01344-w_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"key":"10.1007\/s13311-023-01344-w_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J Intern Med"},{"key":"10.1007\/s13311-023-01344-w_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0962280210386207","article-title":"Diagnosing and responding to violations in the positivity assumption","volume":"21","author":"Petersen","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"10.1007\/s13311-023-01344-w_bib17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/pds.4846","article-title":"Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution","volume":"28","author":"Glynn","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-023-01344-w_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2013a simulation study","volume":"172","author":"St\u00fcrmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1007\/s13311-023-01344-w_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/biomet\/asn055","article-title":"Dealing with limited overlap in estimation of average treatment effects","volume":"96","author":"Crump","year":"2009","journal-title":"Biometrika"},{"key":"10.1007\/s13311-023-01344-w_bib20","unstructured":"Optum. Data Assets Chart Sheet [online]. Eden Prairie, MN; 2015. Accessed at: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf. Accessed 24 Nov 2020."},{"key":"10.1007\/s13311-023-01344-w_bib21","unstructured":"Optum. Cliniformatics Data Mart [online]. Eden Prairie, MN; 2017. Accessed at: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf. Accessed 4 Nov 2020."},{"key":"10.1007\/s13311-023-01344-w_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep."},{"key":"10.1007\/s13311-023-01344-w_bib23","unstructured":"Multum [online]. Denver, CO: Cerner Corporation; 2021. Accessed at: https:\/\/www.cerner.com\/solutions\/drug-database. Accessed 5 Feb 2021."},{"key":"10.1007\/s13311-023-01344-w_bib24","first-page":"227","article-title":"Treating painful diabetic peripheral neuropathy: an update","volume":"94","author":"Snyder","year":"2016","journal-title":"Am Fam Physician"},{"key":"10.1007\/s13311-023-01344-w_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1212\/WNL.0000000000001492","article-title":"Impairments and comorbidities of polyneuropathy revealed by population-based analyses","volume":"84","author":"Hoffman","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01344-w_bib26","unstructured":"2018 ICD-10 CM and GEMs [online]. Baltimore, MD: U.S. Centers for Medicare & Medicaid Services; 2018. Accessed at: https:\/\/www.cms.gov\/Medicare\/Coding\/ICD10\/2018-ICD-10-CM-and-GEMs. Accessed 18 Jan 2021."},{"key":"10.1007\/s13311-023-01344-w_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1007\/s13311-023-01344-w_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","article-title":"Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?","volume":"21","author":"Pham Nguyen","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-023-01344-w_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000365590","article-title":"A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends","volume":"43","author":"Butt","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1007\/s13311-023-01344-w_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.parkreldis.2012.09.014","article-title":"Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States","volume":"19","author":"Willis","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-023-01344-w_bib31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2019.1631160","article-title":"Brivaracetam efficacy and safety in focal epilepsy","volume":"19","author":"Makke","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-023-01344-w_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/epi.13691","article-title":"Accuracy of claims-based algorithms for epilepsy research: revealing the unseen performance of claims-based studies","volume":"58","author":"Moura","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-023-01344-w_bib33","unstructured":"Chronic Conditions Data Warehouse. Condition Categories [online]. Centers for Medicare & Medicaid Services; 2019. Accessed at: https:\/\/www.ccwdata.org\/web\/guest\/condition-categories. Accessed 22 Oct 2021."},{"key":"10.1007\/s13311-023-01344-w_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1007\/s13311-023-01344-w_bib35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1007\/s13311-023-01344-w_bib36","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1007\/s13311-023-01344-w_bib37","unstructured":"Cavazzoni P. 2020: A strong year for new drug therapy approvals \u2013 despite many COVID-19 challenges [online]. U.S. Food and Drug Administration; 2021. Accessed at: https:\/\/www.fda.gov\/news-events\/fda-voices\/2020-strong-year-new-drug-therapy-approvals-despite-many-covid-19-challenges. Accessed 18 Jan 2021."},{"key":"10.1007\/s13311-023-01344-w_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01344-w_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01344-w_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2018.1386553","article-title":"A resurging boom in new drugs for epilepsy and brain disorders","volume":"11","author":"Younus","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1007\/s13311-023-01344-w_bib41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01344-w_bib42","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"First approval","volume":"80","author":"Risdiplam","year":"2020","journal-title":"Drugs"},{"key":"10.1007\/s13311-023-01344-w_bib43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-023-01344-w_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-023-01344-w_bib45","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1007\/s13311-023-01344-w_bib46","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/ajg.2010.334","article-title":"Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study","volume":"105","author":"van Boxel","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1007\/s13311-023-01344-w_bib47","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","article-title":"Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs","volume":"52","author":"MacDonald","year":"2003","journal-title":"Gut"},{"issue":"8","key":"10.1007\/s13311-023-01344-w_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.5432","article-title":"Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists","volume":"31","author":"Rebordosa","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-023-01344-w_bib49","doi-asserted-by":"crossref","first-page":"I14.010","DOI":"10.1212\/WNL.86.16_supplement.I14.010","article-title":"Comparing anti-epileptic drug preferences between neurologists and patients: results from a national survey and discrete choice experiment (I14.010)","volume":"86","author":"Ettinger","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01344-w_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"3","key":"10.1007\/s13311-023-01344-w_bib51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jagp.2021.07.018","article-title":"Medicare claims data underestimate hallucinations in older adults with dementia","volume":"30","author":"Hamedani","year":"2022","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01344-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:34:27Z","timestamp":1761806067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1878747923000867"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01344-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Channeling of New Neuropsychiatric Drugs\u2014Impact on Safety and Effectiveness Studies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01344-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}